OBJECTIVES: To examine hepatitis C virus (HCV) and HIV testing patterns within the Northwest Veterans Integrated Service Network (VISN 20). METHODS: Using a comprehensive VISN 20 database, we retrospectively reviewed medical records of 293,445 veterans. RESULTS: 32.8% of patients were tested for HCV, 5.5% were tested for HIV, and 4.3% were co-tested. Of those tested, 12.3% were HCV positive, 5.4% were HIV positive, and 1.6% were co-infected. 79.1% of HIV-positive patients were tested for HCV, 29.2% of whom tested positive. 34.8% of HCV-positive patients were tested for HIV, 4.9% of whom tested positive. Of those tested, HCV-positive patients were significantly more likely than HCV-negative patients to test positive for HIV; HIV-positive patients were no more likely to test positive for HCV than HIV-negative patients. HIV-positive patients with substance use disorders (SUD) were significantly more likely to test HCV positive than those without. Within the total sample, veterans with SUD were significantly more likely to be tested for both diseases and to test positive for HCV but not HIV. After controlling for other categories of SUD, veterans with a history of cocaine abuse compared with those without were at an increased risk of HIV infection and co-infection. CONCLUSION: 79.1% of HIV-positive but only 34.8% of HCV-positive veterans were co-tested, suggesting barriers to HIV testing may exist in VISN 20. Results also indicate that HCV-positive patients are at increased risk for HIV infection and that HIV-positive patients with SUD are at increased risk of HCV infection; routine co-testing for these patients is therefore warranted. Given significant co-infection rates, HCV and HIV screening and testing should be increasingly integrated. Increased infection rates among patients with SUD also warrant integration of HCV and HIV screening and testing into mental health and addiction programmes.
OBJECTIVES: To examine hepatitis C virus (HCV) and HIV testing patterns within the Northwest Veterans Integrated Service Network (VISN 20). METHODS: Using a comprehensive VISN 20 database, we retrospectively reviewed medical records of 293,445 veterans. RESULTS: 32.8% of patients were tested for HCV, 5.5% were tested for HIV, and 4.3% were co-tested. Of those tested, 12.3% were HCV positive, 5.4% were HIV positive, and 1.6% were co-infected. 79.1% of HIV-positivepatients were tested for HCV, 29.2% of whom tested positive. 34.8% of HCV-positive patients were tested for HIV, 4.9% of whom tested positive. Of those tested, HCV-positive patients were significantly more likely than HCV-negative patients to test positive for HIV; HIV-positivepatients were no more likely to test positive for HCV than HIV-negative patients. HIV-positivepatients with substance use disorders (SUD) were significantly more likely to test HCV positive than those without. Within the total sample, veterans with SUD were significantly more likely to be tested for both diseases and to test positive for HCV but not HIV. After controlling for other categories of SUD, veterans with a history of cocaine abuse compared with those without were at an increased risk of HIV infection and co-infection. CONCLUSION: 79.1% of HIV-positive but only 34.8% of HCV-positive veterans were co-tested, suggesting barriers to HIV testing may exist in VISN 20. Results also indicate that HCV-positive patients are at increased risk for HIV infection and that HIV-positivepatients with SUD are at increased risk of HCV infection; routine co-testing for these patients is therefore warranted. Given significant co-infection rates, HCV and HIV screening and testing should be increasingly integrated. Increased infection rates among patients with SUD also warrant integration of HCV and HIV screening and testing into mental health and addiction programmes.
Authors: Marilyn Huckans; Adriana Seelye; Jonathan Woodhouse; Tiffany Parcel; Lisa Mull; Daniel Schwartz; Alex Mitchell; David Lahna; Amy Johnson; Jennifer Loftis; Steven Paul Woods; Suzanne H Mitchell; William Hoffman Journal: J Clin Exp Neuropsychol Date: 2010-08-06 Impact factor: 2.475
Authors: Benjamin J Morasco; David W Greaves; Travis I Lovejoy; Dennis C Turk; Steven K Dobscha; Peter Hauser Journal: Pain Med Date: 2016-06-27 Impact factor: 3.750
Authors: Mardge H Cohen; Dennis Grey; Judith A Cook; Kathryn Anastos; Eric Seaberg; Michael Augenbraun; Pam Burian; Marion Peters; Mary Young; Audrey French Journal: J Gen Intern Med Date: 2007-10-09 Impact factor: 5.128
Authors: Srigayatri Bollepalli; Kathleen Mathieson; Beata Jasiurkowski; Amy Hillier; John Post; Shakil Bhanu; Dean Martin; David H Van Thiel; Abdul Nadir Journal: Dig Dis Sci Date: 2007-06-12 Impact factor: 3.199
Authors: Marilyn Huckans; Adriana Seelye; Tiffany Parcel; Lisa Mull; Jonathan Woodhouse; Danell Bjornson; Bret E Fuller; Jennifer M Loftis; Benjamin J Morasco; Anna W Sasaki; Daniel Storzbach; Peter Hauser Journal: J Int Neuropsychol Soc Date: 2009-01 Impact factor: 2.892
Authors: Corina Lelutiu-Weinberger; Enrique R Pouget; Don D C Des Jarlais; Hannah L Cooper; Roberta Scheinmann; Rebecca Stern; Shiela M Strauss; Holly Hagan Journal: Soc Sci Med Date: 2008-12-04 Impact factor: 4.634